Sydney biosensor specialist Ambri (ASX:ABI) appeared to hit a setback last week, when the company announced that its US partner would no longer work to develop Ambri's ion-channel switch (ICS).

Biosensor Enterprises (BEL) will no longer work to develop Sydney-based Ambri's (ASX:ABI) ion-channel switch (ICS), and will instead focus on out-licensing the technology.

Sydney-based Pharmaxis (ASX:PXS) has appointed former Structural Genomix VP of drug discovery Ian Macdonald to the position of chief technical officer.

Sydney biosensor developer Ambri (ASX:ABI) has decided to bypass 'Go' with its SensiDx point-of-care biochip system, and fast-track second-generation chip capable of performing up to six different antibody tests simultaneously.

Starpharma (ASX:SPL) today cast off the shackles of its pooled development fund status, and changed its name to Starpharma Holdings Limited. The company also completed a placement of 9 million shares at AUD$0.84, raising $7.56 million.

Sydney bio-nano company Ambri has raised AUD$15.5 million through a placement of ordinary shares to a mix of existing and new institutional investors, and simultaneously announced it will write off $20.7 million worth of IP value from its accounts.

US giant Dow Corning's investment in Australian nanotechnology has deepend with a series of high-profile Dow-related appointments to the board and management of Starpharma's US subsidiary Dendritic Nanotechnologies.

Medical diagnostics company Ambri is striving to tap fresh funding sources while engaging in further staff and cost cutbacks to stretch dwindling cash reserves.

Dr Joe Shaw, the managing director and CEO of Sydney-based biosensor specialist Ambri (ASX: ABI), has resigned from the company and will return to the US.

Listed biotech Ambri Ltd has laid off 15 staff in response to unexpected manufacturing problems in scaling up its biosensor technology for commercial production.

Sydney biosensor specialist Ambri is leveraging newly-forged ties with two high-profile US corporates to negotiate lucrative R&D contracts with the US military.